The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Overcoming immuno-oncology resistance in lung cancer
Roy S. Herbst, MD, PhD, Yale School of Medicine, New Haven, CT, discusses the issue of immuno-oncology (IO) resistance in lung cancer. The combination of ipilimumab and nivolumab in has shown responses for lung cancer in a resistance setting. With an increase in patients become resistant to immunotherapy, the addition of a CTLA-4 inhibitor may overcome this. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
